We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VYEPTI (Lundbeck Australia Pty Ltd)
Product name
VYEPTI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
213 (255 working days)
Active ingredients
eptinezumab
Registration type
NCE/NBE
Indication
VYEPTI (concentrated injection for dilution for infusion) is indicated for the preventive treatment of migraine in adults.